Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


04.03.2019

3 BJU Int
1 Br J Cancer
2 Clin Cancer Res
2 Eur J Radiol
5 Eur Urol
2 Int J Cancer
4 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 J Cell Physiol
1 J Clin Oncol
1 J Nucl Med
3 J Urol
1 Lancet Oncol
1 Nat Rev Urol
8 Oncogene
1 PLoS Genet
2 PLoS One
1 Prostate
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. KE Y, Taylor J, Gao LL, Wang H, et al
    Twitter Response to the 2018 United States Preventive Services Task Force Guidelines on Prostate Cancer Screening.
    BJU Int. 2019 Feb 27. doi: 10.1111/bju.14734.
    PubMed     Text format     Abstract available

  2. MADERTHANER L, Furrer MA, Studer UE, Burkhard FC, et al
    More extended lymph node dissection template at radical prostatectomy detects metastases in the common iliac region and in the fossa of Marcille.
    BJU Int. 2018;121:725-731.
    PubMed     Text format     Abstract available

  3. MISCHINGER J, Kaufmann S, Russo GI, Harland N, et al
    Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy.
    BJU Int. 2018;121:791-798.
    PubMed     Text format     Abstract available


    Br J Cancer

  4. DUTTO L, Ahmad A, Urbanova K, Wagner C, et al
    Correction: Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts.
    Br J Cancer. 2019 Feb 27. pii: 10.1038/s41416-019-0408.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  5. BJARTELL A
    New hope in prostate cancer precision medicine? miRNA replacement and epigenetics.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-19-0061.
    PubMed     Text format     Abstract available

  6. URABE F, Matsuzaki J, Yamamoto Y, Kimura T, et al
    Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-18-2849.
    PubMed     Text format     Abstract available


    Eur J Radiol

  7. AMINSHARIFI A, Gupta RT, Tsivian E, Sekar S, et al
    Reduced Core Targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging - transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies - An alternative template for prostate fusion biopsy.
    Eur J Radiol. 2019;110:7-13.
    PubMed     Text format     Abstract available

  8. BARRETT T, Lawrence EM, Priest AN, Warren AY, et al
    Repeatability of diffusion-weighted MRI of the prostate using whole lesion ADC values, skew and histogram analysis.
    Eur J Radiol. 2019;110:22-29.
    PubMed     Text format     Abstract available


    Eur Urol

  9. WALLIS CJD, Klotz L, Klaassen Z
    Re: Prostate Cancer-specific Mortality Across Gleason Scores in Black vs Nonblack Men.
    Eur Urol. 2019 Feb 25. pii: S0302-2838(19)30162.
    PubMed     Text format    

  10. SAUTER G, Clauditz T, Steurer S, Wittmer C, et al
    Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.
    Eur Urol. 2018;73:674-683.
    PubMed     Text format     Abstract available

  11. MARSHALL CH, Sokolova AO, McNatty AL, Cheng HH, et al
    Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Eur Urol. 2019 Feb 20. pii: S0302-2838(19)30110.
    PubMed     Text format     Abstract available

  12. WIRTH M, Fossati N, Albers P, Bangma C, et al
    The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting.
    Eur Urol. 2019 Feb 21. pii: S0302-2838(19)30077.
    PubMed     Text format     Abstract available

  13. PRENSNER JR, Feng FY
    "Lincing" the Y Chromosome to Prostate Cancer: TTTY15 Takes Center Stage.
    Eur Urol. 2019 Feb 21. pii: S0302-2838(19)30158.
    PubMed     Text format    


    Int J Cancer

  14. PEREZ-CORNAGO A, Huybrechts I, Appleby PN, Schmidt JA, et al
    Intake of Individual Fatty Acids and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32233.
    PubMed     Text format     Abstract available

  15. MARIN-AGUILERA M, Reig O, Mila-Guasch M, Font A, et al
    The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32238.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  16. TRAN PT, Feng F, Ost P
    Live to SABR Another Day?
    Int J Radiat Oncol Biol Phys. 2018;100:1097.
    PubMed     Text format    

  17. MENDIRATTA P, Garcia J
    Androgen Deprivation Fortified.
    Int J Radiat Oncol Biol Phys. 2018;100:1098.
    PubMed     Text format    

  18. SONG D
    Apply an Oligometastatic Paradigm for Nodal Recurrence.
    Int J Radiat Oncol Biol Phys. 2018;100:1098-1099.
    PubMed     Text format    

  19. ONG WL, Evans S, Millar J
    In Regard to Yang et al.
    Int J Radiat Oncol Biol Phys. 2018;100:1294-1295.
    PubMed     Text format    


    Int J Urol

  20. ARAI T, Kojima S, Yamada Y, Sugawara S, et al
    Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: Regulation of NCAPH by antitumor miR-199a/b-3p.
    Int J Urol. 2019 Feb 28. doi: 10.1111/iju.13911.
    PubMed     Text format     Abstract available


    J Cell Physiol

  21. CAO R, Ke M, Wu Q, Tian Q, et al
    AZGP1 is androgen responsive and involved in AR-induced prostate cancer cell proliferation and metastasis.
    J Cell Physiol. 2019 Feb 28. doi: 10.1002/jcp.28366.
    PubMed     Text format     Abstract available


    J Clin Oncol

  22. GULLEY JL, Borre M, Vogelzang NJ, Ng S, et al
    Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2019 Feb 28:JCO1802031. doi: 10.1200/JCO.18.02031.
    PubMed     Text format     Abstract available


    J Nucl Med

  23. LIU T, Liu C, Xu X, Liu F, et al
    Preclinical evaluation and pilot clinical study of Al(18)F-PSMA-BCH for prostate cancer imaging.
    J Nucl Med. 2019 Feb 22. pii: jnumed.118.221671. doi: 10.2967/jnumed.118.221671.
    PubMed     Text format     Abstract available


    J Urol

  24. STOVSKY M, Klein EA, Chait A, Manickam K, et al
    Clinical Validation of IsoPSA, a Single Parameter, Structure-Based Assay for Improved Detection of High-Grade Prostate Cancer.
    J Urol. 2019 Feb 15:101097JU0000000000000185. doi: 10.1097/JU.0000000000000185.
    PubMed     Text format     Abstract available

  25. FEI B, Abiodun-Ojo OA, Akintayo AA, Akin-Akintayo O, et al
    Feasibility and Initial Results: Fluciclovine PET/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.
    J Urol. 2019 Feb 28:101097JU0000000000000200. doi: 10.1097/JU.0000000000000200.
    PubMed     Text format     Abstract available

  26. GREENLAND NY, Zhang L, Cowan JE, Carroll PR, et al
    Correlation of a Commercial Genomic Risk Classifier with Histologic Patterns in Prostate Cancer.
    J Urol. 2019 Feb 15:101097JU0000000000000175. doi: 10.1097/JU.0000000000000175.
    PubMed     Text format     Abstract available


    Lancet Oncol

  27. BURKI T
    Darolutamide for non-metastatic, castration-resistant prostate cancer.
    Lancet Oncol. 2019 Feb 21. pii: S1470-2045(19)30102.
    PubMed     Text format    


    Nat Rev Urol

  28. TAYLOR RA, Fraser M, Rebello RJ, Boutros PC, et al
    The influence of BRCA2 mutation on localized prostate cancer.
    Nat Rev Urol. 2019 Feb 26. pii: 10.1038/s41585-019-0164.
    PubMed     Text format     Abstract available


    Oncogene

  29. MCCLURG UL, Chit NCTH, Azizyan M, Edwards J, et al
    Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12.
    Oncogene. 2018;37:4679-4691.
    PubMed     Text format     Abstract available

  30. POLLAN SG, Huang F, Sperger JM, Lang JM, et al
    Regulation of inside-out beta1-integrin activation by CDCP1.
    Oncogene. 2018;37:2817-2836.
    PubMed     Text format     Abstract available

  31. WANG Y, Li X, Liu W, Li B, et al
    MicroRNA-1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer.
    Oncogene. 2019 Feb 26. pii: 10.1038/s41388-019-0760.
    PubMed     Text format     Abstract available

  32. ZHANG M, Suarez E, Vasquez JL, Nathanson L, et al
    Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity.
    Oncogene. 2019;38:1121-1135.
    PubMed     Text format     Abstract available

  33. BAI S, Cao S, Jin L, Kobelski M, et al
    A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer.
    Oncogene. 2019 Feb 28. pii: 10.1038/s41388-019-0768.
    PubMed     Text format     Abstract available

  34. KATO M, Placencio-Hickok VR, Madhav A, Haldar S, et al
    Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner.
    Oncogene. 2019;38:716-730.
    PubMed     Text format     Abstract available

  35. SEIDI K, Jahanban-Esfahlan R, Monhemi H, Zare P, et al
    NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
    Oncogene. 2018;37:3967-3980.
    PubMed     Text format     Abstract available

  36. O'BRYANT D, Wang Z
    The essential role of WD repeat domain 77 in prostate tumor initiation induced by Pten loss.
    Oncogene. 2018;37:4151-4163.
    PubMed     Text format     Abstract available


    PLoS Genet

  37. BROWN AJ, Mao P, Smerdon MJ, Wyrick JJ, et al
    Nucleosome positions establish an extended mutation signature in melanoma.
    PLoS Genet. 2018;14:e1007823.
    PubMed     Text format     Abstract available


    PLoS One

  38. ANTICO M, Prinsen P, Cellini F, Fracassi A, et al
    Real-time adaptive planning method for radiotherapy treatment delivery for prostate cancer patients, based on a library of plans accounting for possible anatomy configuration changes.
    PLoS One. 2019;14:e0213002.
    PubMed     Text format     Abstract available

  39. TAKAKUSAGI Y, Kawamura H, Okamoto M, Kaminuma T, et al
    Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: A retrospective study.
    PLoS One. 2019;14:e0211370.
    PubMed     Text format     Abstract available


    Prostate

  40. LEE SI, Roney MSI, Park JH, Baek JY, et al
    Dopamine receptor antagonists induce differentiation of PC-3 human prostate cancer cell-derived cancer stem cell-like cells.
    Prostate. 2019 Feb 28. doi: 10.1002/pros.23779.
    PubMed     Text format     Abstract available


    Urology

  41. ASAFU-ADJEI D, Mikkilineni N, Sebesta E, Hyams E, et al
    Misinformation on the Internet regarding Ablative Therapies for Prostate Cancer.
    Urology. 2019 Feb 25. pii: S0090-4295(19)30205.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: